Verastem (VSTM) in the Pivotal Point Check: Convincing Study Data for KRAS-G12D Cancer Therapy Propels Biotech Stock Upward!
Reading Time: 2 minutes
Exemplary Study Results: The drug candidate VS-7375 achieves a response rate of up to 50% in pancreatic cancer. Secured Capacities: A successful issuance of over 250 million USD secures the clinical Phase 3 development. Clear Accelerator: The FDA grants Priority Review for the approval application of the blister pack in Q1 2027. Verastem is a biopharma company focused on developing targeted cancer therapies. The stock experienced a spectacular surge on October 14 and 15, 2026. The trigger for this rally was outstanding study data on...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
